期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

蛋白质组学技术在前列腺癌血清标志物筛选中的应用 被引量：2

暂未订购
导出
作者 燕东亮 刘池波
机构地区 浙江省台州市立医院泌尿外科 浙江省台州市立医院中心实验室
出处 《放射免疫学杂志》 CAS 2009年第5期498-500,共3页 Journal of Radioimmanology
基金 浙江省医学卫生科技项目(2006A123) 浙江省台州市科技局科研基金(061KY22)
关键词 蛋白质组学技术 血清标志物 前列腺癌 前列腺特异抗原 诊断敏感性 筛选 血清PSA 肿瘤标志物
分类号 R392.11 [医药卫生—免疫学] R512.62 [医药卫生—内科学]
  • 相关文献

参考文献2

二级参考文献10

  • 1Jemal A, Thomas A, Murray T, et al. Cancer Statistics[J].CA Cancer J Clin,2002,52(1):23- 47.
  • 2Cooperberg MR, Park S, Carroll PR. Prostate cancer 2004: insights from national disease registries[J].Oncology (Huntingt),2004,18(10):1239-1247.
  • 3Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer[J].Nature,2001,412(6849):822-826.
  • 4Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior[J].Cancer Cell,2002,1(2):203-209.
  • 5Anderson L, Seilhamer J: A comparison of selected mRNA and protein abundances in human liver[J].Electrophoresis,1997,18(3-4):533-537.
  • 6Liu BCS, LaRose I, Weinstein LJ, et al. Expression of telomerase subunits in normal and neoplastic prostate epithelial cells isolated by laser capture microdissection[J].Cancer,2001,92(7):1943-1948.
  • 7Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer[J].Science,1994,266(5193):2011-2015.
  • 8Weinberger SR, Dalmasso EA, Fung ET: Current achievements using ProteinChip Array technology[J].Curr Opin Chem Biol,2001,6(1):86-91.
  • 9Wang S, Diamond DL, Hass GM, et al. Identification of prostate specific membrane antigen(PSMA) as the target of monoclone antibody 107-1A4 by ProteinChip Array, surface-enhanced laser desorption/ionization(SELDI)[J].Int J Cncer,2001,92(6):871- 876.
  • 10黄成,樊嘉.蛋白质芯片SELDI-TOF-MS技术在肿瘤学研究中的应用[J].国外医学（肿瘤学分册）,2004,31(6):434-437. 被引量：3

共引文献34

同被引文献38

  • 1Gr6nberg H. Prostate cancer epidemiology[J]. Lancet,2003, 361 (9360) :859-864.
  • 2Heidenreieh A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer[J]. Eur Urol, 2008,53 (1) : 68-80.
  • 3Stamey TA, Caldwell M, McNeal JE, et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? [J]. J Urol, 2004,172(4 Pt 1) :1297-1301.
  • 4Evans CA, Glen A, Eaton CL, et al. Prostate cancer pro- teomics: The urgent need for clinically validated biomarkers [J]. Proteomics Clin Appl,2009,39(2):197-212.
  • 5Wasinger VC, Cordwell SJ, Cerpa Poljak A, et aI. Progress with germ-product mapping of the mollicutes: Mycoplasma genitalium[J]. Electrophoresis, 1995,16(7) : 1090-1094.
  • 6Marte B. Nature insight: Proteomics[J]. Nature, 2003,422 (6928) : 191-193.
  • 7Haaash S. Disease proteomics[J]. Nature,2003,422(6928): 226-232.
  • 8Chen ZC. Advances in cancer pmteomics study[J]. Ai Zheng, 2004,23(2) :113-117.
  • 9Ahram M. An introduction into proteomics and its clinical ap- plications[J]. Saudi Med J,2007,28(4) ,499-507.
  • 10Gao X, Porter AT, Grignon DJ, et al. Diagnostic and prog- nostic markers for human prostate cancer[M]. Prostate, 1997,31(4) :264-281.

引证文献2

二级引证文献4

放射免疫学杂志
2009年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部